Objective To evaluate the expression level and clinical significance of LYRM4⁃AS1 in glioma patients, as well as its related mechanisms. Methods RNA⁃seq data and clinical data of glioma patients were obtained from the TCGA database. The expression of LYRM4⁃AS1 in tumor and normal tissues was studied, and then the relationship between LYRM4⁃AS1 and the clinicopathological characteristics of patients with glioma was analyzed. Kaplan⁃Meier survival curve and Cox regression analysis were used to evaluate the clinical significance of LYRM4⁃AS1. The potential biological mechanism of LYRM4⁃AS1 was discussed through functional enrichment analysis. Results The study found that compared with normal tissues, LYRM4⁃AS1 was highly expressed in a variety of tumor tissues, and was related to WHO grade (P<0.001), IDH status (P<0.001), and 1p/19q coding loss (P<0.001), primary therapy outcome (P<0.001), EGFR status (P<0.001) and age (P<0.001). Prognostic analysis found that glioma patients with LYRM4⁃AS1 overexpressing had worse OS (HR=3.99, 95%CI=3.01-5.30, P<0.001), DSS (HR=4.00, 95%CI=2.98-5.37, P<0.001) and PFI (HR=2.68, 95%CI=2.13-3.38, P<0.001). Multivariate Cox regression found that LYRM4⁃AS1 was an independent risk factor for prognosis. Finally, functional enrichment analysis found that LYRM4⁃AS1 was related to inflammation and immune response. Conclusion LYRM4⁃AS1 may be a potential diagnosis, treatment and prognostic marker, and it may play a role in the occurrence and development of glioma through inflammation and immune response.